MAG
IMDX

Millrace Asset Group’s Insight Molecular Diagnostics IMDX Stock Holding History

Millrace Asset Group’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-30,694
Closed -$2.19M – 85
2021
Q3 		$2.19M Buy
30,694
+13,748
+81% +$1.26M 1.37% 35
2021
Q2 		$1.95M Buy
16,946
+5,544
+49% +$541K 1.01% 52
2021
Q1 		$1.18M Buy
+11,402
New +$1.08M 0.64% 73

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Millrace Asset Group's IMDX Position: Q4 2021 in Review

Millrace Asset Group sold out of Insight Molecular Diagnostics (IMDX) in Q4 2021, closing a stake of 30,694 shares — an estimated $2.19M sold.

Millrace Asset Group first reported a position in IMDX in Q1 2021 and held it in 3 quarters. The position peaked at $2.19M in Q3 2021. 88 funds tracked by Wall St. Rank hold IMDX as of Q4 2021.

  • Millrace Asset Group reported no remaining Insight Molecular Diagnostics position as of Q4 2021 after selling out during the quarter.
  • Millrace Asset Group sold 30,694 Insight Molecular Diagnostics shares in Q4 2021, an estimated $2.19M.
  • Millrace Asset Group first reported a position in Insight Molecular Diagnostics in Q1 2021 and held it in 3 quarters.
  • Millrace Asset Group's Insight Molecular Diagnostics position peaked at $2.19M in Q3 2021.
  • 88 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2021.

Based on Millrace Asset Group's 13F filing for Q4 2021, filed 14 Feb 2022.